[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594523":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":57,"slug":26,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":82,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"autologous platelet plasma group","ACTIVE_COMPARATOR","diabetic-related wounds after wound bed preparation are treated by the autologous platelet plasma",[13],"Drug: autologous platelet plasma",{"label":15,"type":16,"description":17,"interventionNames":18},"allogeneic platelet plasma group","EXPERIMENTAL","diabetic-related wounds after wound bed preparation are treated by the allogeneic platelet plasma",[19],"Drug: allogeneic platelet plasma",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","allogeneic platelet plasma","Al-PRP derived from healthy blood donors",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"autologous platelet plasma","Autologous platelet-rich plasma from the patient themselves",[9],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Long Zhang Executive Deputy Director, Medical Doctor","CONTACT","+86 010-82266699","liyunfeng1106@163.com",[38],{"facility":5,"status":26,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Beijing","Beijing Municipality","100191","China",{"type":44,"coordinates":45},"Point",[46,47],116.39723,39.9075,{"lat":47,"lon":46},[50,52],{"name":51,"role":34,"phone":26,"phoneExt":26,"email":36},"Yunfeng Li, Medical Doctor",{"name":51,"role":53,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Long Zhang","Head of Wound Healing Center","100594523",false,"NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial","Comparing Allogeneic Versus Autologous Platelet-Rich Plasma for Diabetic Wound Healing in Patients With Renal Dysfunction：a Randomized Controlled Trial","Inclusion Criteria:\n\n1. The patient is aged 18-80 years old;\n2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;\n3. Abnormal renal function defined as:\n\n   * Serum creatinine \\>106 μmol\u002FL (men) or \\>97 μmol\u002FL (women)\n   * AND eGFR \\\u003C90 mL\u002Fmin\u002F1.73m² (CKD-EPI) ；\n4. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;\n5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met\\*;\n6. Voluntarily sign an informed consent form;\n\nExclusion Criteria:\n\n1. Blood glucose is out of control or not yet effectively controlled，;\n2. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n3. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；\n4. Uncontrolled systemic or disseminated infections;\n5. Patients with advanced malignant tumors;\n6. Pregnant or lactating women；\n7. The patient is unable to cooperate or has mental disorders;\n8. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.","ALL","18 Years","80 Years",{"count":67,"type":68},56,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.",[74,75,76,77],"Diabetic Wounds","Platelet Rich Plasma","Allogeneic Blood Transfusions","Renal Dysfunction",[79,75,80,81],"Diabetic wounds","allogeneic blood","renal dysfunction","NOT_YET_RECRUITING","2025-08-23",{"date":85,"type":86},"2025-08-26","ACTUAL",{"date":88,"type":68},"2026-04",{"date":90,"type":68},"2028-05",{"name":5,"class":6},1]